FDA secukinumab coverage for business development, investment, and market access teams
Cosentyx has received FDA approval for moderate to severe hidradenitis suppurativa, marking a significant advancement in treatment options for affected patients.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
